DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs
Open Access
- 21 September 2017
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 13 (12) , 3010-3019
Abstract
We previously developed optimized DNA vaccines against both Lassa fever and Ebola hemorrhagic fever viruses and demonstrated that they were protective individually in guinea pig and nonhuman primate models. In this study, we vaccinated groups of strain 13 guinea pigs two times, four weeks apart with 50 µg of each DNA vaccine or a mock vaccine at discrete sites by intradermal electroporation. Five weeks following the second vaccinations, guinea pigs were exposed to lethal doses of Lassa virus, Ebola virus, or a combination of both viruses simultaneously. None of the vaccinated guinea pigs, regardless of challenge virus and including the coinfected group, displayed weight loss, fever or other disease signs, and all survived to the study endpoint. All of the mock-vaccinated guinea pigs that were infected with Lassa virus, and all but one of the EBOV-infected mock-vaccinated guinea pigs succumbed. In order to determine if the dual-agent vaccination strategy could protect against both viruses if exposures were temporally separated, we held the surviving vaccinates in BSL-4 for approximately 120 days to perform a cross-challenge experiment in which guinea pigs originally infected with Lassa virus received a lethal dose of Ebola virus and those originally infected with Ebola virus were infected with a lethal dose of Lassa virus. All guinea pigs remained healthy and survived to the study endpoint. This study clearly demonstrates that DNA vaccines against Lassa and Ebola viruses can elicit protective immunity against both individual virus exposures as well as in a mixed-infection environment.Keywords
This publication has 20 references indexed in Scilit:
- Temporal Progression of Lesions in Guinea Pigs Infected With Lassa VirusVeterinary Pathology, 2016
- Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challengesHuman Vaccines & Immunotherapeutics, 2015
- Ebola virus in West Africa: new conquered territories and new risks—or how I learned to stop worrying and (not) love Ebola virusCurrent Opinion in Virology, 2015
- DNA vaccines for HFRS: Laboratory and clinical studiesVirus Research, 2014
- DNA Vaccination in Skin Enhanced by Electroporation2014
- Tolerability of intramuscular and intradermal delivery by CELLECTRA®adaptive constant current electroporation device in healthy volunteersHuman Vaccines & Immunotherapeutics, 2013
- Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal ElectroporationVaccines, 2013
- Evaluation of Lassa antiviral compound ST-193 in a guinea pig modelAntiviral Research, 2011
- Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation deviceGene Therapy, 2010
- Cutting Edge: Impairment of Dendritic Cells and Adaptive Immunity by Ebola and Lassa VirusesThe Journal of Immunology, 2003